focus -WSS

focus

author：focus 2025-10-01 20:16:05 - browse：64

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Bird flu researchers hone in on Finland’s mink farms

entertainment

WSS

David Sabatini, ex

Aspartame and sugar

Dozens dead from Maui wildfires: What we know about the victims

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Judge sides with young activists in first

Startling documents reveal new facets of Sacklers' opioid empire

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

Indictment alleges Trump's ex

Activists slam private health insurers over coverage restrictions

Mark Cuban is blaming the wrong people for high drug costs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Report: NIH

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Psychedelics group wrestles with new pharma identity

Health insurers say they are turning to AI to cut costs, improve care

knowledge

Dozens dead from Maui wildfires: What we know about the victims

Akili, maker of video game for ADHD, to be acquired for 34 million

Be careful with at

Addiction doctors spar with methadone clinics over legislation

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

knowledge

entertainment

Wikipedia

entertainment